Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens

American Journal of Clinical Pathology

Volumn 132, Issue 2, 2009, Pages 211-220

  Trpkov, Kiril ^a   Bartczak McKay, Joanna ^a   Yilmaz, Asli ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Methylacyl CoA racemase; AMACR; Cytokeratin 5 6; Double immunohistochemistry; Immunohistochemistry; P504S; Prostate carcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYTOKERATIN 5; CYTOKERATIN 6;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC TEST; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE BIOPSY; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; MALE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 68549094541     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPGFJP83IXZEUR     Document Type: Article

References (45)

1. Hendrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13:389-396.
2. Wojno KJ, Epstein JI. The utility of basal-cell specific anticytokeratin antibody 34βE12 in the diagnosis of prostate cancer. Am J Surg Pathol. 1995;19:251-260.
3. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
4. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596.
5. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase, a useful marker for the diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1173.
6. Yang XJ, Wu CL, Woda BA, et al. Expression of alphamethyl-acyl CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26:921-925.
7. Kunju LP, Rubin MA, Chinnaiyan AM, et al. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol. 2003;120:737-745.
8. Magi-Galluzzi C, Luo J, Isaacs WB, et al. Alpha-methylacyl-CoA racemase: a variable sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol. 2003;27:1128-1133.
9. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27:772-778.
10. Zhou M, Aydin H, Kanane H, et al. How often does alphamethylacyl-CoA racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol. 2004;28:239-243.
11. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol. 2004;35:1272-1278.
12. Browne T-J, Hirsch MS, Brodsky G, et al. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004;12:1462-1468.
13. Jiang Z, Iczkowski KA, Woda BA, et al. P504S immunostaining boosts diagnostic resolution in "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol. 2004;121:99-107.
14. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker for prostate basal cells. Mod Pathol. 2002;15:1302-1308.
15. Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal-cell -specific markers 34βE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168.
16. Zhou M, Shah R, Shen R, et al. Basal cell cocktail (34βE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003;27:365-371.
17. Shah RB, Kunju LP, Shen R, et al. Usefulness of basal cell cocktail (34βE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004;122:517-523.
18. Molinie V, Fromont G, Sibony M, et al. Diagnostic utility of a p63/alpha-methyl-acyl-CoA racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17:1180-1190.
19. Sanderson SO, Sebo TJ, Murphy LM, et al. Analysis of the p63/α-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol. 2004;121:220-225.
20. Tacha DE, Miller RT. Use of p63/p504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue. Appl Immunohistochem Mol Morphol. 2004;12:75-78.
21. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methyl acyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 420 foci in radical prostatectomy and needle biopsy tissue. Am J Surg Pathol. 2005;29:579-587.
22. Hameed O, Humphrey PA. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol. 2005;124:708-715.
23. Molinie V, Herve JM, Lugagne PM, et al. Diagnostic utility of a p63/alpha-methyl coenzyme A racemase (p504s ) cocktail in ambiguous lesions of the prostate upon needle biopsy. BJU Int. 2006;97:1109-1115.
24. Jiang Z, Li C, Fisher A, et al. Using AMACR (P504S)/34βE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005;123:231-236.
25. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinoma of the prostate. Am J Surg Pathol. 2007;31:889-894.
26. Ng VWL, Koh M, Tan SY, et al. Is triple immunostaining with 34βE12, p63 and racemase in prostate cancer advantageous? a tissue microarray study. Am J Clin Pathol. 2007;127:248-253.
27. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002;41:35-41.
28. Abrahams NA, Bostwick DG, Ormsby AH, et al. Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6. Am J Clin Pathol. 2003;120:368-376.
29. Trpkov K, Chiu E. Utility of cytokeratin 5/6 and AMACR as a routine immunopanel for the diagnosis of prostate cancer on needle core biopsy [abstract]. Mod Pathol. 2004;17:181A.
30. Trpkov K, Yilmaz A. Cytokeratin 5/6 and alphamethylacyl-CoA racemase (AMACR) are useful in evaluating prostate specimens after therapy [abstract]. Virchows Arch. 2005;447:196.
31. Reis-Filho J, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
32. Trpkov K, Renault P, Yilmaz A, et al. IBF as a formalin substitute fixative in prostate biopsy pathology [letter]. Arch Pathol Lab Med. 2006;130:13-14.
33. Trpkov K, Warman L. Use of digital maps and sampling of radical prostatectomy specimens [letter]. Arch Pathol Lab Med. 2006;130:1751-1752.
34. Nakanishi H, Wang X, Ochai A, et al. A nomogram for predicting low-volume/low grade prostate cancer: a tool in selecting patients for active surveillance. Cancer. 2007;110:2441-2447.
35. Adley BP, Yang XJ. α-Methyl-acyl-CoA racemase immunoreactivity in partial atrophy of the prostate. Am J Clin Pathol. 2006;126:849-855.
36. Wang W, Sun X, Epstein JI. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol. 2008;32:851-857.
37. Jiang Z, Wu CL, Woda BA, et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004;45:218-225.
38. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62:2220-2226.
39. Helpap B. The significance of P504S expression pattern of high-grade intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in the biopsy and radical prostatectomy specimens. Virchows Arch. 2006;448:480-484.
40. Wu CL, Yang XJ, Tretiakova M, et al. Analysis of α-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol. 2004;35:1008-1113.
41. Varma M, Linden MD, Amin MB. Effect of formalin fixation and epitope retrieval techniques on antibody 34βE12 immunostaining of prostatic tissue. Mod Pathol. 1999;12:472-478.
42. Iczkowski KA, Cheng L, Crawford BG, et al. Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34betaE12 to discriminate cancer in prostatic epithelium. Mod Pathol. 1999;12:1-4.
43. Multhaupt HA, Fessler JN, Warhol MJ. Loss of high-molecular-weight cytokeratin antigenicity in prostate tissue obtained by transurethral resections. Arch Pathol Lab Med. 2000;124:1764-1767.
44. Burford HN, Adams AL, Hameed O. Effect of storage on p63 immunohistochemistry: a time-course study [published online ahead of print September 23, 2008]. Appl Immunohistochem Mol Morphol. 2009;17:68-71.
45. Tsui J, Trpkov C, Gao Y, et al. Pathology findings in 6825 ten-core prostate needle biopsies: a single centre community experience [abstract]. Mod Pathol. 2005;18:168A.